The effects of cyclooxygenase and nitric oxide synthase inhibition on cardiodynamic parameters and coronary flow in isolated rat hearts

Experimental and Clinical Cardiology

Volumn 18, Issue 2, 2013, Pages

  Zivkovic, Vladimir ^a   Djuric, Dragan ^b   Turjacanin Pantelic, Drenka ^b   Marinkovic, Zeljko ^a   Stefanovic, Djordje ^a   Srejovic, Ivan ^a   Jakovljevic, Vladimir ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cardiac function; Coronary flow; COX inhibitors; Isolated rat hearts

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; MELOXICAM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME INHIBITION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART RATE; ISOLATED HEART; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 84879913061     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Santos M, Kunkar V, Iturralde PG, Tendillo FJ. Meloxicam, a specific COX-2 inhibitor, does not enhance the isoflurane minimum alveolar concentration reduction produced by morphine in the rat. Anesth Analg 2004;98:359-63.
2. Yamamoto T, Cohen AM, Kakar NR, et al. Production of prostanoids and nitric oxide by infracted heart in situ and the effect of aspirin. Biochem Biophys Res Commun 1999;257:488-93.
3. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-20.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997;336:973-9.
5. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997;77:333-7.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
7. Karmazyn M, Neely Jr. Evidence for a direct protective effect pf aspirin on the ischemic and reperfused heart. Circulation 1988;78:16.
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-28.
9. Gottlieb S. COX 2 inhibitors may increase risk of heart attack. BMJ 2001;323:471.
10. Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 2008;17:601-8.
11. Sorensen R, Abildstrom SZ, Torp-Pedersen C, Gislason GH. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. J Cardiovasc Nurs 2008;23:14-9.
12. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 2004;37:71-7.
13. Straino S, Salloum FN, Baldi A, et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 2007;50:571-7.
14. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 2004;286:H1416-24.
15. Timmers L, Sluijter JP, Verlaan CW, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;23:326-32.
16. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994.
17. Moncada S, Higgs EA, Vane Jr. Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation. Lancet 1977;1:18.
18. Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmitters. Sci Signal Sci Signal 2009;2:re2.
19. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
20. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274:5038-46.
21. Novokmet S, Jakovljevic VLj, Jankovic S, et al. Human platelets perfusion through isolated guinea-pig heart: The effects on coronary flow and oxidative stress markers. Gen Physiol Biophys 2009;28:98-104.
22. Green, LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.
23. Kawabata H, Sugiyama K, Katori R. Effect of acetylsalicylic acid on metabolism and contractility in the ischemic reperfused heart. Jpn Circ J 1996;60:961-71.
24. Fu Y, Wang Z, Chen WL, Moore PK, Zhu YZ. Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol 2007;293:H1545-52
25. Rossoni G, Muscara MN, Cirino G, Wallace JL. Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol 2002;135:1540-6.
26. Shultz R, Nava E, Moncada S. Induction and potential biological relevance of Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-80.
27. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37.
28. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13.
29. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50:470-9.
30. Moreno-Sánchez R, Bravo C, Vásquez C, Ayala G, Silveira LH, Martínez-Lavín M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: Study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999;57:743-52.
31. Timmers L, Sluijter JP, Verlaan CW, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;23:326-32.
32. Carnieto A Jr, Dourado PM, Luz PL, Chagas AC. Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo) 2009;64:245-52.
33. Birkenmeier K, Staudt A, Schunck WH, et al. COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia. Am J Physiol Heart Circ Physiol 2007;293:H2148-54.
34. Schoemaker RG, Saxena PR, Kalkman EA. Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. Cardiovasc Res 1998;37:108-14.
35. Samuelsson B, Granström E, Green K, Hamberg M, Hammarström S. Prostaglandins. Annu Rev Biochem 1975;44:669-95.
36. Schröder H. Nitric oxide and aspirin: A new mediator for an old drug. Am J Ther 2009;16:17-23.
37. Ignarro LJ. Nitric oxide: A unique endogenous signaling molecule in vascular biology. Biosci Rep 1999;19:51-71.
38. Höcherl K, Dreher F, Kurtz A, Bucher M. Cyclooxygenase-2 inhibition attenuates lip polysaccharide-induced cardiovascular failure. Hypertension 2002;40:943.
39. Félétou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011;164:894-912.
40. Jakovljevic VL, Kostic MM, Mujovic VM, Nedeljkovic TI, Duric DM. Interaction between L-arginine/NO system and cyclooxigenase metabolic product of arachidonic acid in coronary autoregulation. J Physiol Pharmacol 1999;50:63-74.
41. Harder DR, Campbell Wb, Roman RJ. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 1995;32:79-92.
42. Rees DD, Palmer RJ, Moncada S. Nitric oxide and microcirculation. In: Nitric oxide from L-arginin: A bioregulatory System. Amsterdam: Excepta Medica 1990;427-38.
43. Kostic MM, Schrader J. Role of nitric oxide in reactive hyperemia of the guinea pig heart. Circ Res 1992;70:208-12.
44. Kostic MM, Pertonijevic MR, Jakovljevic VLJ. Role of nitric-oxide in the regulation of coronary circulation. Physiol Res 1996;45:273-78.
45. Baracho NC, Guizelli GP, Carmello BL, et al. Cardiovascular and hematologic effects produced by chronic treatment with etoricoxib in normotensive rats. Acta Cir Bras 2009;24:206-10.
46. Wilson DP, Susnjar M, Kiss E, Sutherland C, Walsh MP. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr- 855, but not Thr-697. Biochem J 2005;389(Pt 3):763-74.
47. Hong TT, Huang J, Barrett TD, Lucchesi BR. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol 2008;294:H145-55.
48. Ogawa N, Mori A, Hasebe M, Hoshino M, et al. Nitric oxide dilates rat retinal blood vessels by cyclooxygenase-dependent mechanisms. Am J Physiol Regul Integr Comp Physiol 2009;297:R968-77. Serbia